Cargando…
The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma
Primary bone marrow lymphoma (PBML) is a rare clinical entity. Because of its rarity, there is no standard therapy defined. Prognosis in this disease is poor, and further studies for effective treatments are needed. In this report, we will discuss a patient with PBML who was treated with a hyper-fra...
Autores principales: | Reed, Allison, Sommerhalder, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155813/ https://www.ncbi.nlm.nih.gov/pubmed/32300465 http://dx.doi.org/10.14740/jh559 |
Ejemplares similares
-
Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
por: Sonnevi, Kristina, et al.
Publicado: (2021) -
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021) -
Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022) -
Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015) -
A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
por: DeRon, Nathan, et al.
Publicado: (2022)